Henrijette Richter

Henrijette Richter is a prominent Managing Partner at Sofinnova Partners since September 2014, along with serving as a Board Member for multiple companies including Mozart Therapeutics, Inc., Nitrase Therapeutics, Muna Therapeutics, Twentyeight-Seven Therapeutics, and NodThera Limited. As Chair of the Board of Directors at iOmx Therapeutics AG and NodThera Limited, Henrijette Richter brings extensive leadership experience to the biotechnology sector. Education includes an executive course in Venture Capital and Private Equity from Harvard Business School, an Executive Certificate from Copenhagen Business School, and a PhD in Molecular Biology from the University of Copenhagen, complemented by postdoctoral research at the Massachusetts Institute of Technology in Oncology and Cancer Biology.